1. Known anaphylaxis to any of the trial vaccine components (including excipients of the trial vaccines) or drugs. 2. Participants with previous documented SARS-CoV-2 infection within 6 months of vaccination day by history obtained from participant(s) and/or positive anti-nucleocapsid test(s). 3. Receipt of immunoglobulins or blood products within 3 months on the day of vaccination. 4. Receipt of any other vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrollment in this trial.

1. Known anaphylaxis to any of the trial vaccine components (including excipients of the trial vaccines) or drugs. 2. Participants with previous documented SARS-CoV-2 infection within 6 months of vaccination day by history obtained from participant(s) and/or positive anti-nucleocapsid test(s). 3. Receipt of immunoglobulins or blood products within 3 months on the day of vaccination. 4. Receipt of any other vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrollment in this trial.